Aura Biosciences
AURA
147 hedge funds and large institutions have $677M invested in Aura Biosciences in 2026 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 58 increasing their positions, 27 reducing their positions, and 15 closing their positions.
147% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 15
115% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 27
99% more capital invested
Capital invested by funds: $340M → $677M (+$337M)
17% more funds holding
Funds holding: 126 → 147 (+21)
12.15% more ownership
Funds ownership: 80.12% → 92.27% (+12%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
84% less call options, than puts
Call options by funds: $175K | Put options by funds: $1.06M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TCG Crossover Management
Palo Alto,
California
|
+$68.2M |
| 2 |
CP
Caligan Partners
New York
|
+$29.1M |
| 3 |
FIS
FCPM III Services
Naarden,
Netherlands
|
+$29M |
| 4 |
O
OrbiMed
New York
|
+$23.8M |
| 5 |
SCM
Suvretta Capital Management
New York
|
+$20.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$3.44M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.73M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$978K |
| 4 |
LCS
Levin Capital Strategies
New York
|
-$739K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$355K |
AURA Hedge Fund Activity: Q2 2026 in Review
147 of the 8,318 institutional investors tracked by Wall St. Rank reported a position in Aura Biosciences (AURA) for Q2 2026, worth a combined $677M — up 99% from $340M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new AURA positions and 15 closed out — a net gain of 22 holders — while 58 added to existing stakes and 27 trimmed.
The largest buyer was TCG Crossover Management, opening a new position worth an estimated $68.2M. The largest seller was Millennium Management, cutting an estimated $3.44M.
- 147 institutional investors held Aura Biosciences (AURA) as of Q2 2026, up from 126 in Q1 2026.
- Funds reported $677M of Aura Biosciences stock for Q2 2026, up 99% quarter-over-quarter.
- 37 funds opened new Aura Biosciences positions in Q2 2026 and 15 closed out, a net change of +22 holders.
- The largest Aura Biosciences buyer in Q2 2026 was TCG Crossover Management, an estimated $68.2M added.
- The largest Aura Biosciences seller in Q2 2026 was Millennium Management, an estimated $3.44M sold.
Based on aggregated 13F filings for Q2 2026.